Alpha-2 Plasmin Inhibitor, Plasma
Use
This test is useful for diagnosing congenital alpha-2 plasmin inhibitor deficiencies, which are rare. It provides a complete assessment of conditions such as disseminated intravascular coagulation, intravascular coagulation and fibrinolysis, and hyperfibrinolysis when measured together with fibrinogen, fibrin D-dimer, fibrin degradation products, soluble fibrin monomer complex, and plasminogen. It is also valuable for evaluating liver disease and assessing the effects of fibrinolytic or antifibrinolytic therapy.
Special Instructions
Not provided.
Limitations
The results of alpha-2 plasmin inhibitor may be affected by heparin (unfractionated or low-molecular-weight >4 U/mL), alpha-2-macroglobulin >7 mg/mL, potentially leading to a falsely increased result, hemoglobin >200 mg/dL, bilirubin >20 mg/dL, and triglycerides >1000 mg/dL.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 27810-1 - Plasm Inhib Act/Nor PPP Chro
- 27810-1 - Plasm Inhib Act/Nor PPP Chro
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light-blue top (3.2% sodium citrate), submission in a plastic vial
Collection Instructions
Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again. Aliquot plasma into a plastic vial leaving 0.25 mL in the bottom of centrifuged vial. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or ideally -40 degrees C or below.
Storage Instructions
Store frozen at -20°C or ideally at -40°C or below.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |